Physician profile
Wayne Campbell
NPI 1417926577
$4,539.08
in general payments reported to CMS, 2019-2025
24 companies · $943 in 2025
The $943 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $924 · 2020: $393 · 2021: $630 · 2022: $387 · 2023: $502 · 2024: $759 · 2025: $943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,204.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,285.39 | 2019-2025 | Breztri, Tezspire, Airsupra |
| Novo Nordisk INC | $1,068.84 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $392.99 | 2019-2021 | |
| Boston Scientific Corporation | $294.08 | 2024-2025 | Watchman Flx |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.60 | 2025 | Caplyta |
| Cvrx, INC. | $125.28 | 2025 | Barostim Neo System |
| Biohaven Pharmaceuticals, INC. | $125.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2022 | |
| Axsome Therapeutics, INC. | $125.00 | 2023 | Auvelity |
| Idorsia Pharmaceuticals US INC | $125.00 | 2023 | Quviviq |
| Esperion Therapeutics, INC. | $125.00 | 2021 | |
| United Therapeutics Corporation | $107.69 | 2023 | |
| Radius Health, INC. | $107.14 | 2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $85.30 | 2019 | |
| Lilly USA, LLC | $80.27 | 2019-2024 | Mounjaro |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $52.64 | 2019 | |
| Merck Sharp & Dohme LLC | $45.28 | 2019 | |
| Amarin Pharma, INC. | $30.79 | 2019 | |
| Novartis Pharmaceuticals Corporation | $27.09 | 2019 | |
| Glaxosmithkline, LLC. | $24.99 | 2019 | |
| Aerin Medical INC. | $19.99 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.54 | 2019 | |
| Allergan, INC. | $12.43 | 2019 | |
| Pfizer INC. | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.